首页
>
期刊首页
>
中草药（英文版）
>
2026年3期
>
Xuezhikang Capsule ameliorates ischemic stroke via multi-target modulation of neurovascular units
Xuezhikang Capsule ameliorates ischemic stroke via multi-target modulation of neurovascular units
摘要
To the Editor,
Ischemic stroke(IS)is a leading cause of disability worldwide,yet no comprehensively effective drug is available for clinical treatment(Virani et al.,2021).Thrombolytic therapy with tissue plasminogen activator(tPA)is limited by a short treatment win-dow and bleeding risk(Campbell & Khatri,2020).Red yeast rice(RYR)has been used for centuries as a food and medicinal agent in Asia.Its standardized extract,Xuezhikang(XZK),contains mona-colins(including monacolin K,identical to lovastatin)and other bioactive constituents(Yang,Wu,Qian,& Li,2024;Ma et al.,2000).XZK exhibits hydroxy methylglutaryl coenzyme A(HMG-CoA)reductase inhibitory activity superior to purified lovastatin and is well-recognized for lipid regulation,anti-inflammatory effects,and vascular protection in cardiovascular diseases(Endo,1979;Moriarty et al.,2014).These properties suggest that XZK may benefit IS,but its direct molecular targets and precise mech-anisms remain unclear.
年，卷(期)：
2026, 18(3)
机标分类号：
P208
R246.6
R395.3
在线出版日期：
2026年8月26日
